Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.34 |
| ▸ | PIP4K2A | P48426 | 4/20 | 0.33 |
| ▸ | PIP4K2B | P78356 | 4/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.31 |
| ▸ | CHRNG | P07510 | 2/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRND | Q07001 | 2/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17651864 | 0.82 | KDM4E (0.37) | — | |
| SCHEMBL9893667 | 0.81 | POLB (0.45) | POLB | |
| SCHEMBL1838200 | 0.80 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL3660018 | 0.75 | CHRNB2 (0.31) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL427184 | 0.75 | HCAR2 (0.33) | — | |
| SCHEMBL458480 | 0.75 | ATM (0.33) | — | |
| SCHEMBL14779948 | 0.74 | ATM (0.48) | CYP11B2POLB | |
| SCHEMBL2067107 | 0.74 | KDM4E (0.32) | — | |
| SCHEMBL584540 | 0.74 | NPC1 (0.35) | POLB | |
| SCHEMBL113201 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-03-21 | — | — | US | disclosed |
| EP-3233085-B1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF EGFR AND PI3K | UNIV MICHIGAN REGENTS (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | disclosed |
| EP-3955923-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | The Regents Of The University Of Michigan (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20210023085-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-01-28 | — | — | US | disclosed |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2020215037-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-06 | — | — | US | disclosed |
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
| EP-3233085-A2 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | The Regents of The University of Michigan (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100347-A2 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | PIK3CB 16/4885DYRK1A 115/4885PIP4K2A 28/4885 |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | PIK3CB 16/4885DYRK1A 115/4885PIP4K2A 28/4885 |
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | PIK3CB 16/4885DYRK1A 115/4885PIP4K2A 28/4885 |
| US-20210023085-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | PIK3CB 16/4885DYRK1A 115/4885PIP4K2A 28/4885 |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | PIK3CB 16/4885DYRK1A 115/4885PIP4K2A 28/4885 |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | PIK3CB 16/4885DYRK1A 115/4885PIP4K2A 28/4885 |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | CD274, PDCD1, PDCD1LG2 | PIK3CB 1530/4885DYRK1A 2359/4885PIP4K2A 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.